AACR-NCI-EORTC 2025 Poster B092

A Preclinical Ex Vivo Model for Glioblastoma Captures Patient Heterogeneity in Drug Response

Ezgi Kaya Aksoy, Ulrica Westermark, Kristin Hammer, Luca Gandini, Jolie Flach, Emma Spanjaard, Stefan Svensson Gelius, Marrit Putker and Nataliia Beztsinna

Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant cancers. To better replicate tumor complexity and patient variability, Crown Bioscience and Oncopeptides developed a 3D Ex Vivo Patient Tissue (EVPT) model that preserves the native microenvironment and heterogeneity of GBM tissue.

This platform enabled screening of approximately 200 Peptide Drug Conjugates (PDCs), identifying compounds with strong cytotoxic activity even in temozolomide resistant samples. The study demonstrates how EVPT can enhance translational relevance and accelerate therapeutic discovery for difficult-to-treat tumors.

Download this Poster to Discover:

• How the EVPT model maintains patient-specific tumor architecture
• Insights into ex vivo screening of PDC compounds for GBM
• Data revealing significant variability in patient drug response
• How EVPT supports faster, more clinically meaningful results

Download the Poster Now!